DoD cuts down EHR modernization contract bidders

In the ongoing saga of the Department of Defense's (DoD) $11 billion contract to modernize its EHR system, a presolicitation notice reveals that the list of competing bidders has been whittled down but does not reveal the remaining contenders. DoD issued a final solicitation last August 2014, with Oct. 31, 2014, as the final date to submit proposals. A team of DoD civilians, military personnel and subject matter and procurement experts are evaluating the proposals and a final decision is expected by June. The project aims to replace the Armed Forces Health Longitudinal Technology Application (AHLTA); Composite Health Care System; and various EHR components, including AHLTA-Theater.

The following teams were competing for the contract:

  • Computer Sciences Corp., a defense contractor and systems integrator; Hewlett Packard; and Allscripts
  • Cerner; Leidos, a government systems integrator; and Accenture Federal
  • IBM and Epic
  • DSS, General Dynamics Information Technology, Google, MedSphere and PricewaterhouseCoopers (PwC)

According to reports, three teams remain in the running but PwC said that its bid for an open-source system was outside of the DoD's newly established competitive range.

Beth Walsh,

Editor

Editor Beth earned a bachelor’s degree in journalism and master’s in health communication. She has worked in hospital, academic and publishing settings over the past 20 years. Beth joined TriMed in 2005, as editor of CMIO and Clinical Innovation + Technology. When not covering all things related to health IT, she spends time with her husband and three children.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.